Deal of the Day — limited-time pharmacy picks!
Rahika 200mg Tablet

Rahika 200mg Tablet

Prescription requiredRx Required

Salt Composition: Capmatinib (200mg)

Expiry Date: 01/2028

Special offer

Price on Request

Price on Request

Inclusive of all taxes

▼

50 Tablet

About The Product

Used in the treatment of non-small cell lung cancer. This drug stops or slows down the growth of cancer cells.

Description

Rahika 200mg tablet is an anticancer targeted based medication that a primary approach in the treatment of non small cell lung cancer. Its active salt formation is Capmatinib present in the strength of 200mg.

It belongs to the drug class of kinase inhibitor or tyrosine kinase inhibitor acts as a MET inhibitor. The medicine works by blocking the key pathway of cancer cells use to multiply.

Healthcare experts suggest using the medication under prescription to ensure safety during the treatment.

Uses

Treat non-small cell lung cancer

Side Effects

Rahika 200mg tablet cause mild or severe side effects in patients. If you experience any of these symptoms consult the healthcare professional immediately:

  • Vomiting
  • Liver injury
  • Muscle pain
  • Shortness of breath
  • Lung infection
  • Respiratory disease
  • Swelling in the face, and body
  • Decrease in appetite
  • Nausea
  • Cough
  • Fatigue

How To Use

  • Always follow the prescription dosage as recommended by the doctor.
  • Take Rahika 200mg tablet orally in 200mg concentration at the same time everyday to enhance the effectiveness of the medication.
  • Do not overdose or skip the medicine without consultation with a doctor as this may interrupt the treatment.

How It Works

Rahika 200mg tablet belongs to the drug class of kinase inhibitor, it acts by blocking the MET receptor kinase, an abnormal protein that promotes the growth and spread of cancer cells.

The medicine also prevents the body from further growing tumors and protects the body from multiplication of cancer cells.

Safety Advice

Alcohol
Rahika 200mg tablet should be taken by avoiding alcohol consumption as it can interrupt the treatment outcomes.
Pregnancy
Dose adjustment should be recommended by the healthcare professional. Rahika 200mg tablet does not cause any harmful effects but still doctor guidance is required.
Breast Feeding
Patient can use Rahika 200mg tablet under doctor prescription as breastfeeding the baby is generally safe.
Driving
Rahika 200mg tablet may cause dizziness and weakness in some patients. Do not drive or operate machinery while using the medication.
Kidney
Rahika 200mg tablet need dose adjustment in kidney patients to avoid complications during the treatment.
Liver
Rahika 200mg tablet should be used by liver patients under doctor guidance because medicine can interfere with the liver functions.

FAQs

Rahika 200mg tablet is used by patients with non small cell lung cancer (NSCLC) by slowing tumor growth and protect the body from further growing cancer in the body.

References

  • Esaki, T., Hirai, F., Makiyama, A., Seto, T., Bando, H., Naito, Y., ... & Doi, T. (2019). Phase I dose‐escalation study of capmatinib (INC 280) in Japanese patients with advanced solid tumors. Cancer Science, 110(4), 1340-1351.
  • Bang, Y. J., Su, W. C., Schuler, M., Nam, D. H., Lim, W. T., Bauer, T. M., ... & Ma, B. (2020). Phase 1 study of capmatinib in MET‐positive solid tumor patients: Dose escalation and expansion of selected cohorts. Cancer science, 111(2), 536-547.
  • Chen, X., Cui, X., Pognan, N., Quinlan, M., Kapoor, S., Rahmanzadeh, G., ... & Marbury, T. C. (2022). Pharmacokinetics of capmatinib in participants with hepatic impairment: A phase 1, open‐label, single‐dose, parallel‐group study. British journal of clinical pharmacology, 88(1), 91-102.
  • Vansteenkiste, J. F., Van de Kerkhove, C., Wauters, E., & Van Mol, P. (2019). Capmatinib for the treatment of non-small cell lung cancer. Expert review of anticancer therapy, 19(8), 659-671.
  • Bi, B., Zhan, J., Fan, B., Fang, W., & Li, S. (2025). The pharmacokinetics of capmatinib and its efficacy in non-small cell lung cancer treatment: a narrative review. Translational Lung Cancer Research, 14(7), 2842.

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026